Literature DB >> 18474585

In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.

Chia-Ying Liu1, Yu-Tsung Huang, Chun-Hsing Liao, Po-Ren Hsueh.   

Abstract

All 198 Salmonella isolates (58.6% of isolates were resistant to tetracycline), 92 Vibrio isolates (4.4% of isolates were resistant to tetracycline), and 200 of 201 Aeromonas isolates (39.3% of isolates were resistant to tetracycline; 1 A. caviae isolate had a tigecycline MIC of 4 mug/ml) in our study were susceptible to tigecycline, by U. S. Food and Drug Administration criteria for Enterobacteriaceae.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18474585      PMCID： PMC2443901          DOI： 10.1128/AAC.00002-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Bacterial food-borne illness outbreaks in northern Taiwan, 1995-2001.

Authors:  Hsun-Pi Su; Shiou-Ing Chiu; Jin-Lai Tsai; Chih-Lung Lee; Tzu-Ming Pan
Journal:  J Infect Chemother       Date:  2005-06       Impact factor: 2.211

2.  Increasing antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan.

Authors:  W C Ko; K W Yu; C Y Liu; C T Huang; H S Leu; Y C Chuang
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.

Authors:  Sarvajna Sacchidanand; Robert L Penn; John M Embil; Maria E Campos; Daniel Curcio; Evelyn Ellis-Grosse; Evan Loh; Gilbert Rose
Journal:  Int J Infect Dis       Date:  2005-09       Impact factor: 3.623

4.  In vitro susceptibilities of tropical strains of Aeromonas species from Queensland, Australia, to 22 antimicrobial agents.

Authors:  J M Koehler; L R Ashdown
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

5.  Increasing ceftriaxone resistance in Salmonella isolates from a university hospital in Taiwan.

Authors:  Lin-Hui Su; Tsu-Lan Wu; Ju-Hsin Chia; Chishih Chu; An-Jing Kuo; Cheng-Hsun Chiu
Journal:  J Antimicrob Chemother       Date:  2005-05-04       Impact factor: 5.790

6.  In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus.

Authors:  Y C Chuang; J W Liu; W C Ko; K Y Lin; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

7.  Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.

Authors:  Thomas R Fritsche; Patty A Strabala; Helio S Sader; Michael J Dowzicky; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2005-07       Impact factor: 2.803

8.  Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.

Authors:  Y C Chuang; W C Ko; S T Wang; J W Liu; C F Kuo; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 9.  Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment.

Authors:  Y C Chuang; C Y Yuan; C Y Liu; C K Lan; A H Huang
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

10.  Aeromonas bacteremia: review of 59 episodes.

Authors:  W C Ko; Y C Chuang
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079
View more
  7 in total

1.  Which antibiotics and breakpoints should be used for Aeromonas susceptibility testing? Considerations from a comparison of agar dilution and disk diffusion methods using Enterobacteriaceae breakpoints.

Authors:  B Lamy; F Laurent; A Kodjo; F Roger; E Jumas-Bilak; H Marchandin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-27       Impact factor: 3.267

2.  Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.

Authors:  Hung-Jen Tang; Chi-Chung Chen; Chun-Cheng Zhang; Kuo Chen Cheng; Shyh-Ren Chiang; Yu-Hsin Chiu; Yee Huang Ku; Wen-Chien Ko; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

3.  In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.

Authors:  Hung-Jen Tang; Wen-Chien Ko; Chi-Chung Chen; Po-Lin Chen; Han Siong Toh; Tzu Chieh Weng; Wen-Liang Yu; Shyh-Ren Chiang; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

4.  In Vitro Synergy and In Vivo Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis.

Authors:  Seong Eun Kim; Hee Kyung Kim; Su-Mi Choi; Yohan Yu; Uh Jin Kim; Kalifa Sanneh Darboe; Seung-Ji Kang; Kyung-Hwa Park; Gaeun Kang; Young Ran Kim; Joon Haeng Rhee; Sook-In Jung; Hee-Chang Jang
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

5.  In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.

Authors:  C-Y Liu; C-L Lu; Y-T Huang; C-H Liao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-08       Impact factor: 3.267

6.  Multidrug-resistant (MDR) Aeromonas recovered from the metropolitan area of Valencia (Spain): diseases spectrum and prevalence in the environment.

Authors:  C Esteve; E Alcaide; M J Giménez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-02       Impact factor: 3.267

7.  Epidemiology, Serogroups and Resistance of Salmonella During a 15-Year Period (2006-2020) in Kuwait.

Authors:  Wafaa Jamal; Fatema Bibi Khodakhast; Manuel John Albert; Vincent Rotimi
Journal:  Infect Drug Resist       Date:  2021-11-25       Impact factor: 4.003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.